References:

1.
World Health Organization. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Geneva, Switzerland: World Health Organization; 2008.
2.
Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1087-1097.
3.
Larouche JF, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol. 2010;28:2094-2100.
4.
Cook JR, Hsi ED. Pathology and molecular genetics of non-Hodgkin’s lymphoma. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:513-530.
5.
Smith SM, van Besien K. Treatment approach to diffuse large B-cell lymphoma. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:543-554.
6.
Sweetenham JW, Heslop HE, Savage KJ. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program. 2005;252-259.
7.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
8.
Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417-1429.
9.
Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384-4399.
10.
Tilly H, Dreyling M; On behalf of the ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):iv110-iv112.
11.
Pazdur R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 10th ed. Lawrence, KS: CMP Media LLC; 2007.
12.
López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23:2797-2804.
13.
The NCCN Non-Hodgkin’s Lymphomas Clinical Practice Guidelines in Oncology (Version 1.2010). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed June 7, 2010.
14.
Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med. 2008;132:118-124.
15.
Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6351-6357.
16.
Marafioti T, Jabri L, Pulford K, Brousset P, Mason DY, Delsol G. Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin’s disease. Br J Haematol. 2003;120:671-678.
17.
Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:961-968.
18.
Gormley RP, Madan R, Dulau AE, et al. Germinal center and activated B-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol. 2005;124:790-798.
19.
Vorob’ev IA, Gorgidze LA, Gretsov EM, et al. Flow fluorimetry in differential diagnosis of diffuse large B-cell lymphoma [in Russian]. Ter Arkh. 2006;78:46-51.
20.
Kimura M, Yamaguchi M, Nakamura S, et al. Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma. Int J Hematol. 2007;85:41-48.
21.
Oh YH, Park CK. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci. 2006;397-405.
22.
Wong HH, Wang J. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma. 2009;50:335-340.
23.
Gascoyne RD, Lamant L, Matrin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102:2568-2573.
24.
Suefuji H, Ohshima K, Hayabuchi N. HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features. Br J Haematol. 2003;123:606-612.
25.
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110:29-36.
26.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
27.
Greer JP, Williams ME. Non-Hodgkin Lymphoma in Adults. In: Greer JP, Foerster J, Rodgers GM, et al, eds. Wintrobe’s Clinical Hematology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:2144-2194.
28.
Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:995-1007.
29.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
30.
Armitage JO, Bierman PJ, Bociek RG, et al. Lymphoma 2006: classification and treatment. Oncology. 2006;20:1-14. http://www.cancernetwork.com/display/article/10165/10788. Accessed May 5th, 2010.
31.
Sweetenham JW. Definition of remission, prognosis, and follow-up in follicular lymphoma and diffuse large B-cell lymphoma. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:701-710.
32.
Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837.
33.
Brusamolino E. First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions. Haematol. 2009;94:1194-1198.
34.
Sehn LH. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Educ Program. 2006:295-302.
35.
Bibb J, Fischer E, Lee S, Libby E, Rabinowitz I. The utility of Bayes’ theorem in positron emission tomography positive suspected cases of relapsed non-Hodgkin’s lymphoma. Internet J Oncol. 2009;6:1-11.
36.
Prichard M, Harris T, Williams ME, Densmore JJ. Treatment strategies for relapsed and refractory aggressive non-Hodgkin’s lymphoma. Expert Opin Pharmacother. 2009;10:983-995.
37.
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
38.
Lenz G, Nagel I, Siebert R, et al. Aberrent immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma. J Exp Med. 2007;204:633-643.
39.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862.
40.
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
41.
Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B-cell lymphoma [letter]. N Engl J Med. 2009;360:2794-2795.
42.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
43.
Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930-4935.
44.
Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subytpes with high accuracy. Clin Cancer Res. 2009;15:5494-5502.
45.
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164-1174.
46.
Portlock C, Vose JM, Cheson BD. Diffuse large B-cell lymphoma. Lymphoma Research Foundation 2009. http://www.lymphoma.org/atf/cf/%7B0363cdd6-51b5-427b-be48-e6af871acec9%7D/DLBCL09A.PDF. Accessed June 2, 2010.
47.
Moskowitz CH. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol. 2006;17(suppl 4):iv37-iv39.
48.
Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am. 2008;46:225-241.
49.
Mey VJ, Jha V, Strehl JW, et al. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. German Med Sci. 2007;5:1-11.
50.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244-1253.
51.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
52.
Gallagher CJ, Lister TA. Follicular non-Hodgkin's lymphoma. Baillieres Clin Haematol. 1987;1:141-155.
53.
Cheson BD. Treatment approaches to follicular lymphoma. In: Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: The McGraw-Hill Companies; 2007:531-542.
54.
Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Educ Program. 2009:532-541.
55.
Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood. 1996;88:3937-3944.
56.
Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005:314-320.
57.
Martinez-Climent JA, Alizadeh AA, Segraves R, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood. 2003;101:3109-3117.
58.
Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol. 1994;12:1349-1357.
59.
Czuczman MS. Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). Hematology Am Soc Hematol Educ Program. 2006:303-310.
60.
Quintás-Cardama A, Wierda W, O’Brien S. Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol. 2010;28:884-892.
61.
US National Institutes of Health. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov. Accessed June 8, 2010.
62.
Briones J. Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther. 2009;9:1305-1316.
63.
Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613-626.
64.
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714-727.
65.
Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119:2143-2159.
66.
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393-4402.
67.
Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:572-577.
68.
Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68:8049-8057.
69.
Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol. 1999;36:15-20.
70.
Cardarelli PM, Rao-Naik C, Chen S, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010;59:257-265.
71.
Hotta T. Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma. Acta Histochem Cytochem. 2002;35:275-279.
72.
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174.
73.
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384-8392.
74.
Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leukemia Res. 2009;33:1233-1242.
75.
Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69:2358-2364.
76.
Zhou HJ, Pham LV, Tamayo AT, et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood. 2007;110:2121-2127.
77.
Feng Y, Ding X, Chen T, et al. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors. J Med Chem. doi:10.1021/jm901004c.
78.
Pan L, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol. 2007;4:337-343.
79.
Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008;45:S11-S16.
80.
Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
81.
Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7:209-219.
82.
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer. 2009;9:550-562.
83.
Leseux L, Hamdi SM, al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006;108:4156-4162.
84.
Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 2003;63:7338-7344.
85.
O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719-726.
86.
Baudot AD, Jeandel PY, Mouska X, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009;28:3261-3273.
87.
Kim SW, Rai D, McKeller MR, Aguiar RC. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood. 2009;113:6153-6160.
88.
Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230-2237.
89.
Terasawa T, Nagai H. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes. Leuk Lymphoma. 2009;50:1750-1752.

Explore BioOncology Resources by Tumor Type

X

Use this Related Resources tool to quickly access topics of interest throughout the site that are relevant to a tumor type.

Select a tumor type to get started

: Related Resources

Learn more about

Tumor Types